Top Abstract Purchase Related
Home
>
Node
>
Subnode

Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia

Song, Y.; Li, N.-c.; Wang, X.-f.; Ma, L.-l.; Wan, B.; Hong, B.-f.; Na, Y.-q.

Zhonghua Nan Ke Xue 11(9): 674-676

2005

ISSN/ISBN: 1009-3591
PMID: 16209208
Document Number: 592771
To study the efficacy and safety of Eviprostat for the treatment of benign prostatic hyperplasia (BPH). An open, multicentral clinical trial was conducted in 100 patients with BPH. Patients received a 12-week oral administration of Eviprostat 2 tablets per-time, 3 times a day. The main indexes of efficacy include international prostatic symptom score (IPSS), maximum urinary flow rate (Qmax), residual urine ( Ru) and prostatic volume (V). The additional indexes are quality of life score (QOL) and average urinary flow rate (Qave). After a 12-week therapy, IPSS, QOL score, Qmax and Qave were significantly improved. IPSS was averagely decreased by 5.67 (P < 0.001); QOL score was averagely decreased by 1.44 (P < 0.001); Qmax was averagely increased by 1.70 ml/s (P <0.001); Qave was averagely increased by 1.15 ml/s (P < 0.001); Ru was averagely decreased by 5.07 ml (P = 0.046) , PSA level was averagely decreased by 0.129 microg/L (P < 0.017). The clinical adverse event rate was 1%. Eviprostat is a kind of safe, effective and preferable drug for treating BPH. It can improve the subjective symptoms and objective measures of the patients.

Document emailed within 1 workday
Secure & encrypted payments

Matsuura, T.; Wakabayashi, A.; Kaneko, S.; Kurita, T. 1986: Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry Hinyokika Kiyo. Acta Urologica Japonica 32(6): 903-906
Yajima, M.; Takemura, H.; Nishida, S.; Matsushita, T.; Yanagisawa, N.; Baba, K.; Iwamoto, T. 1999: Clinical study of transurethral electrovaporization of the prostate for benign prostatic hyperplasia Hinyokika Kiyo. Acta Urologica Japonica 45(9): 609-612
Guo, X-Kun.; Bian, J.; Nie, Y.; Zhang, Z-Xiang.; Li, W-Li.; Zhang, Y.; Gao, W-Yang.; Feng, Y-Ju.; Cheng, S-Ping.; Xiang, Y-Jiu. 2003: Experimental study of vasoligation in the treatment and prevention of benign prostatic hyperplasia Zhonghua Nan Ke Xue 9(1): 20-23
Tveter, K.J.; Beisland, H.O.; Andersen, J.T.; Wolf, H.; Ekman, P.; Johansson, J.E.; Kontturi, M.; Lehtonen, T. 1996: Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 116(27): 3226-3230
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Jonas, U.; Melchior, H.; Rübben, H. 1998: Recommendations for billing alternative therapy of benign prostatic hyperplasia. Laser therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 37(1): 110-111
Schulman, C.C.; Zlotta, A.R. 1994: Transurethral needle ablation (TUNA): histopathological, radiological and clinical studies of a new office procedure for treatment of benign prostatic hyperplasia Progress in Clinical and Biological Research 386: 479-486
Bauer, H.W.; Casarosa, C.; Cosci, M.; Fratta, M.; Blessmann, G. 1999: Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study MMW Fortschritte der Medizin 141(25): 62
Madsen, F.A.; Bruskewitz, R.C. 1995: Clinical manifestations of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 291-298
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Schneider, H.J.; Honold, E.; Masuhr, T. 1995: Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices Fortschritte der Medizin 113(3): 37-40
Gorilovskiĭ, L.M. 1995: Permixon in the treatment of benign prostatic hyperplasia Terapevticheskii Arkhiv 67(8): 62-64
McConnell, J.D. 1995: Benign prostatic hyperplasia. Hormonal treatment Urologic Clinics of North America 22(2): 387-400
Kumanov, H.; Mladenov, D.; Nikolov, S.; Penkov, R.; Stratev, S.; Kotzev, R.; Petkova, L.; Ganev, T.; Uzunov, A.; Uzunov, N. 1998: Treatment of benign prostatic hyperplasia with tamsulosin Khirurgiia 53(6): 38-41
Ekman, P.; Andersen, J.T.; Wolf, H. 1996: Finasteride in the treatment of benign prostatic hyperplasia Acta Urologica Belgica 64(1): IX-XII
Zhang, X-Hua. 2008: Current clinical management strategies for benign prostatic hyperplasia Chinese Medical Journal 121(17): 1759-1760
Effert, P.; Ackermann, R. 1992: Clinical manifestations and indications for therapy of benign prostatic hyperplasia Der Urologe. Ausg. a 31(3): 135-141
Wu, X.-j.; Yang, L.-y.; Zhang, X.-z. 2008: A clinical analysis of benign prostatic hyperplasia with chronic prostatitis Zhonghua Nan Ke Xue 14(6): 527-529
Ustinov, D.V.; Kholtobin, D.P.; Kul'chavenia, E.V.; Aĭzikovich, B.I. 2013: The use of laser vaporization for the treatment of benign prostatic hyperplasia Urologiia 4: 74
Moon, L.; Pfettscher, S. 1995: Hytrin treatment of hypertension and benign prostatic hyperplasia Anna Journal 22(3): 335-336